Nothing Special   »   [go: up one dir, main page]

EP4324458A1 - Triple stabilizer system - Google Patents

Triple stabilizer system Download PDF

Info

Publication number
EP4324458A1
EP4324458A1 EP23190167.9A EP23190167A EP4324458A1 EP 4324458 A1 EP4324458 A1 EP 4324458A1 EP 23190167 A EP23190167 A EP 23190167A EP 4324458 A1 EP4324458 A1 EP 4324458A1
Authority
EP
European Patent Office
Prior art keywords
ionic surfactant
based polymer
substance
cellulose based
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23190167.9A
Other languages
German (de)
French (fr)
Inventor
Adrian Dobrowolski
Elisabeth KERSTEN
Michael Ostendorf
Werner Hoheisel
Christoph NÜBOLDT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP22190372.7A external-priority patent/EP4324457A1/en
Application filed by Bayer AG filed Critical Bayer AG
Publication of EP4324458A1 publication Critical patent/EP4324458A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Definitions

  • Stabilizer systems are commonly used in the wet comminution of a poorly soluble active ingredients for the production of nanosuspensions, i.e. suspensions in which the active ingredient is present as particles in the submicron range (d90 ⁇ 1 ⁇ m). Apart from stabilizing the poorly soluble active ingredients during production of nanosuspensions, the stabilizer systems are also often required to stabilize these active ingredient nanoparticles in the nanosuspensions themselves. Generally, employed are water-soluble polymers for steric stabilization and charged (ionic) surfactants for electrostatic stabilization of the active ingredient nanoparticles. For example Li et al.
  • stabilizing polymers there is a concentration limitation for certain stabilizing polymers, either because their solubility in water is too low or because the viscosity becomes too high for comminution at higher polymer concentrations.
  • cellulose derivatives such as hydroxypropyl cellulose (HPC)
  • HPC hydroxypropyl cellulose
  • the concentration of the active ingredient had to be reduced if HPC was used as stabilizing polymer, thereby also reducing the concentration of the stabilizing polymer until a viscosity was reached that allowed processing and/or that allowed stabilization of the active ingredient nanoparticles in the nanosuspensions.
  • active ingredients that are preferably stabilized with HPC could only be produced as a lower concentrated nanosuspension. Consequently, compared to higher concentrated suspensions, several batches had to be milled to produce a required amount of active ingredient nanoparticles. Therefore, there was a need to provide higher concentration suspensions of substances stabilized with HPC.
  • particle refers to a solid, gel, or semisolid material having a relatively small size and characterized in that as said particles have a solubility of less than 10g/l in a suspension comprising water, matrix forming polymer(s) and optionally surfactants as determined e.g. by HPLC.
  • micro-particle which is used synonymously with microparticle refers to particles having an average particle size of between > 999 nm to 100 ⁇ m.
  • the employed micro-particles have an average d90 of between 2 ⁇ m and 50 ⁇ m, more preferably between 2 ⁇ m and 30 ⁇ m, most preferably between 2 ⁇ m and 20 ⁇ m.
  • nano refers to particles having an average particle size - i.e. d50 of the distribution - of ⁇ 10 nm to ⁇ 999 nm.
  • the nanoparticles have a particle size distribution of d90 ⁇ 2 ⁇ m, preferably ⁇ 1 ⁇ m, especially preferred ⁇ 500 nm and d50 ⁇ 1 ⁇ m, preferably ⁇ 500 nm, especially preferred ⁇ 200 nm.
  • the particle size distribution can be determined by methods known in the art such as laser diffraction or Dynamic Light Scattering (DLS).
  • the term d50 or d90 means that 50% or 90% of the total product volume consists of particles smaller than the given value for d50 or d90.
  • the given particle size corresponds to the hydrodynamic particle size when determined by DLS (dynamic light scattering), laser diffraction or electron microscopy and for all methods an equivalent size for spheres is given and meant here.
  • a person skilled in the art is capable of choosing technical equipment suitable for achieving a respective d50 or d90 value. For example it is clear to a skilled person that using an agitated ball mill will result in a smaller d50 and d90 values than using a planetary ball mill, especially if the agitated ball mill is cooled.
  • Laser diffraction was used to determine the particle size said laser diffraction was performed in a Malvern Mastersizer 3000. Suspensions (nano- and micro-) were directly injected into the storage tank of Master sizer 3000 without addition of further excipients.
  • the Mastersizer 3000 was equipped with a Hydro MV unit, where deionized water was provided to disperse and dilute the sample further. The dispersed sample was added to the Hydro MV unit until the obscuration reached 5%.
  • the mixer of the Hydro MV unit was set to 2500 rpm. The first three measurements were performed with red and blue laser lights using the Mie light scattering model. Three measurements were performed without ultrasonic.
  • active ingredient refers to an agent, active ingredient, compound, substance, compositions, or mixtures thereof, that provides a pharmacological and/or agrochemical effect.
  • critical micelle concentration refers to the minimum concentration of surfactants which is necessary to form a colloidal system, in particular micelles, in a self-assembly process.
  • the critical micelle concentration can be determined as described in A. Fernández, N. González, W. Iglesias, and L. Montenegro (1997) Determination of Critical Micelle Concentration of Some Surfactants by Three Techniques, J. Chemical Education, 74:1227-1231 .)
  • the CMC is measured via surface tension measurements with a tensiometer.
  • Surfactant solutions with different concentrations are prepared and characterized with tensiometer as described in Masouk et al. 2022. Before CMC the surface tension is decreasing with increasing surfactant concentration. At CMC the surface tension is no longer reduced with increasing surfactant concentration.
  • Fig. 5 shows that surfactants which show no reduction of CMC (indicator for poor interaction with polymer) with PVP in the system (Na-Deoxycholate) do not influence the viscosity reduction of the triple-stabilizer-system. Hence a skilled person can determine whether a given surfactant is suitable for the composition described herein.
  • non-ionic surfactant refers to surfactants that do not have any ions.
  • the non-ionic surfactant sterically stabilizes the nano-particles and is hence also referred to as steric stabilizer.
  • composition comprising
  • the remaining weight percentage proportion of the composition described herein is water.
  • the water is distilled water and/or sterile water.
  • the non-ionic surfactant via adding the non-ionic surfactant to generate a triple stabilizer system, it became possible to increase concentration of the at least one cellulose-based polymer while still maintaining the viscosity in a range suitable for comminution/milling. Due to the higher cellulose based polymer concentration also concentration of the substance with a solubility in water between 0.0001 g/l and 10 g/l could be increased. Thus, employing the non-ionic surfactant resulted in a more economic process since the comminution has to be repeated less times.
  • the particles size distribution (PSD) of the nanoparticles derived from the composition described herein remained almost exactly constant after drying and redispersing compared to the PSD of the nanoparticles derived from the composition described herein prior to drying.
  • Viscosity can be measured for example via rotational viscosimeter, capillary viscosimeter, falling sphere viscosimeter or dip cup viscosimeter which all are established methods and well known to a person skilled in the art.
  • An example for a rotational viscosimeter is the modular compact rheometer MCR102e by Anton Paar.
  • a shear rate range is specified, and the viscosity is measured as a function of the shear rate.
  • the substance of a particle size between 1 ⁇ m and 100 ⁇ m and a solubility in water between 0.0001 g/l and 10 g/l is an active ingredient hence the composition described herein comprises in an aqueous suspension
  • composition described herein could also comprise more than one substance e.g. a mixture of two active ingredients. However, in practice this embodiment seems unlikely due to regulatory requirements regarding active ingredients.
  • the cellulose-based polymer is selected from methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxybutylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, sodiumcarboxymethylcellulose, carboxymethylethylcellulose and carboxyalkylcellulose More preferably the cellulose based polymer is selected from hydroxymethylcellulose (HPMC) and hydroxypropylcellulose (HPC).
  • HPMC hydroxymethylcellulose
  • HPC hydroxypropylcellulose
  • HPC is used as cellulose based polymer.
  • the composition comprises HPC in a range of between 2 wt% and 3 wt%.
  • the anionic surfactant is chosen from the group consisting of sodium dodecyl sulfate (SDS), sodium docusate (dioctyl sodium sulfosuccinate) and/or sodium oleate.
  • the anionic surfactant is sodium dodecyl sulfate (SDS).
  • redispersible powders As described in WO2021069350A1 .
  • redispersible powders it is meant that these powders, with the addition of the at least equal amount of water removed during drying, form a suspension with a size distribution where again the d90 is ⁇ 1 ⁇ m. If the suspension has a higher concentration less water has to be evaporated during drying to obtain the desired amount of redispersible powder ( WO2021069350A1 ).
  • the surfactant can be selected from any surfactant (i.e. charged or non-charged) as long as the critical micelle concentration of the surfactant is influenced by the cellulose based polymer (indicator for good interaction between anionic surfactant and used polymers / nonionic surfactants). If this is the case than the surfactant is suitable.
  • Surfactants known to a skilled person include charged surfactant selected from acylamino acids (and salts thereof), such as: acylglutamates, for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium acaprylglutamate; acylpeptides, for example palmitoyl hydrolyzed milk protein, sodium cocoyl hydrolyzed soy protein and sodium/potassium cocoyl hydrolyzed collagen; Sarcosinates, for example, myristoyl sarcosine, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate; Taurates, for example, sodium lauroyl taurate and sodium methyl cocoyl taurate; acyl lactylates, luroyl lactylate, caproyl lactylate, alaninates; carboxylic acids and derivatives, such as: carboxylic acids, for example lauric
  • alkyl aryl sulfonates for example sodium coco monoglyceride sulfate, sodium C-olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG cocamide sulfate, sulfosuccinates, for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate; as well as sulfuric acid esters, such as alkyl ether sulfate, for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C-pareth sulfate, alkyl sulfates, for example sodium, ammonium and
  • non-ionic surfactants are polyvinylpyrrolidone-vinylacetate-copolymer, polymethracrylate-derivates, and polyvinylpyrrolidone (PVP).
  • Polyvinylpyrrolidones (especially K12 and K30 types) and N-vinylpyrrolidone-vinyl acetate copolymers are particularly preferred.
  • the polymer can be a copolymer of ethylene oxide and propylene oxide, in particular a poloxamer, or a polyvinylpyrrolidone, in particular PVPK30.
  • non-ionic surfactant is characterized by a molecular weight between 2,000 g/mol and 16,000g/mol preferably between 3,000 g/mol and 8,000 g/mol and is termed a "low molecular weight non-ionic surfactant ".
  • non-ionic surfactant is characterized by a molecular weight between 18.000 g/mol and 50.000g/mol preferably between 22.000 g/mol and 44.000 g/mol and termed a "high molecular weight non-ionic surfactant ".
  • the composition comprises 0.01 wt% to 10 wt% low molecular weight non-ionic surfactant or 0.01 wt% to 5wt% high molecular weight non-ionic surfactant.
  • polyvinylpyrrolidone is used as non-ionic surfactant.
  • the low molecular weight non-ionic surfactant is PVP K12.
  • the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 4:1 and 1:4.
  • the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2. In an especially preferred embodiment of the of the composition the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1:1, as this ratio is optimal for the generation of re-dispersible powders.
  • the concentration of the substance of a particle size between 1 ⁇ m and 100 ⁇ m in the range of 10.1 wt% to 12 wt%.
  • the solubility of the substance of a particle size between 1 ⁇ m and 100 ⁇ m in water is in the range of between 0.001g/l and 1 g/l.
  • the composition consist of at least one active ingredient of a particle size between 1 ⁇ m and 100 ⁇ m and a solubility in water between 0.001 g/l and 1 g/l, HPMC as cellulose based polymer, SDS as anionic surfactant, PVP12 as low molecular weight non-ionic surfactant , wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 4:1 and 1:4, wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1:1 and wherein the concentration of the active ingredient of a particle size between 1 ⁇ m and 100 ⁇ m and a solubility in water between 0.001 g/l and 10 g/l is in the range of 10.1 wt% to 12 wt%.
  • the composition consist of at least one active ingredient of a particle size between 1 ⁇ m and 100 ⁇ m and a solubility in water between 0.001 g/l and 1 g/l, 2 wt% HPC as cellulose based polymer, SDS as anionic surfactant, PVP12 as low molecular weight non-ionic surfactant, wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 4:1 and 1:4, wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1:1 and wherein the concentration of the active ingredient of a particle size between 1 ⁇ m and 100 ⁇ m and a solubility in water between 0.001 g/l and 10 g/l is in the range of 10.1 wt% to 12 wt%.
  • the composition consist of at least one active ingredient of a particle size between 1 ⁇ m and 100 ⁇ m and a solubility in water between 0.001 g/l and 1 g/l, 3 wt% of HPC as cellulose based polymer, SDS as anionic surfactant, PVP12 as low molecular weight non-ionic surfactant, wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 4:1 and 1:4, wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1:1 and wherein the concentration of the active ingredient of a particle size between 1 ⁇ m and 100 ⁇ m and a solubility in water between 0.001 g/l and 10 g/l is in the range of 10.1 wt% to 12 wt%.
  • the composition is further processed to form a re-dispersible powder as described in WO2021069350A1 .
  • the composition in this case is further process via nano-grinding thereby providing a composition comprising nano-particles of the substance characterized by a nano-particle size of a d90 between 10 nm and 999 nm as measured by Dynamic Light Scattering (DLS), laser diffraction or electron microscopy.
  • DLS Dynamic Light Scattering
  • Suitable methods of nano-grinding can be selected from the group consisting of wet bead milling in stirred media mills, wet bead milling in planetary mills - especially suitable for small amounts - and high pressure homogenization.
  • the application of high shear forces in aqueous suspensions like in a high pressure homogenization process or the application of high impact forces between the particles like in a microfluidizer can be used to produce nano-particles.
  • nano grinding is used for providing the seeding material (i.e. production of nanoscale crystals) said nano grinding can only be performed if the nano-particles are not completely dissolved.
  • a suitable temperature within the temperature range of between 253 K and 323 K, preferably between 273 K and 303 K for nano-grinding the nano-particles in the aqueous suspension.
  • a preferred nano-grinding time is observed during grinding in order to achieve better redispersion of the dried powder containing nanoparticles.
  • This preferred grinding time (t-preferred) is significantly longer than the grinding time that would typically be required to achieve the necessary particle size.
  • said preferred grinding time (t-preferred) is at least 1.5 times t0, preferably it is at least 2 times t0 and particularly preferably at least 4 times t0.
  • t0 is considered to be the usual grinding time at which the d90 value of the particle size distribution is 1.5 times the d90 value reached after 12 hours and is referred to as d90(12h).
  • d90 (12h) is 2/3 of the d90 value at the usual grinding time t0.
  • Grinding time is understood to mean the residence time of the suspension in the mill, which explicitly means that the possible residence time of the suspension in an optionally present holding tank is not counted towards the grinding time, i.e. towards the comminution time (tz).
  • the composition is spray dried according to step B) of the method described in WO 2021/069350 and to form a powder and optionally further process to form a tablet.
  • step B of the method described in WO 2021/069350 and to form a powder and optionally further process to form a tablet.
  • the particles size distribution (PSD) of the nanoparticles derived from the composition described herein remained almost exactly constant after drying and redispersing compared to the PSD of the nanoparticles derived from the composition described herein prior to drying.
  • PSD particles size distribution
  • drying and redispersion of a composition comprising nanoparticles obtained from the composition described herein in aqueous media that do not bring about complete molecular dissolution of the substance lead to the particle size distribution (PSD) of the original composition comprising nanoparticles obtained from the composition described herein remaining almost exactly constant hence differs by comparison with the PSD of the redispersed powder only by a factor X within a range from ⁇ 1 to ⁇ 3, based on the d 90 value of the respective suspensions.
  • X here corresponds to the ratio n/v, where n represents the d 90 value of the PSD after drying and redispersion and v the d 90 value before drying.
  • X is particularly preferably ⁇ 1 to ⁇ 1.2.
  • the composition is processed via nano-grinding and spray drying the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1: 1.
  • the seeding material i.e. the nano crystals
  • the seeding material can be provided via high pressure homogenization, or antisolvent precipitation.
  • this aspect relates to a method for producing a composition comprising nano-particles starting from the composition described herein, wherein the method comprises the following steps:
  • this method and the resulting re-dispersible powder have the advantage that a high concentration of active ingredient can be processes and the particles size distribution (PSD) of the nanoparticles remains almost exactly constant after drying and redispersing compared to the PSD of the nanoparticles derived from the composition described herein prior to drying.
  • PSD particles size distribution
  • Said composition for use as a medicament is preferably a nano-suspension.
  • Said composition is preferably manufactured via the method for producing a composition comprising nano-particles described above.
  • Composition A was an aqueous i.e. water-based suspension comprised as substance an active ingredient (10.5 wt%, here Rivaroxaban), as the at least one cellulose-based polymer hydroxypropylcellulose (HPC) 2 wt%, as the at least one anionic surfactant a charged surfactant here SDS (0.2% SDS) and as the at least one non-ionic surfactant a low molecular weight non-ionic surfactant PVP K12 (8 wt%) and 79.3 wt% water.
  • Composition B comprised 10.5 wt % active ingredient (here Rivaroxaban), 10 wt % HPC and 0.2 wt % SDS. The components of both compositions were stirred on a magnetic stirrer at room temperature.
  • Viscosity was measured with rotational viscometry with a modular compact rheometer (MCR) 302e (Anton Paar). A concentric cylinder geometry was used. Shear rate was varied logarithmic from 0.1 1/s to 1000 1/s. 6 measurement points per decade were used. The measurement time was varied form 10s for a shear rate of 0.1 1/s and 1s for 1000 1/s. Shear rate vs. Shear stress was plotted. The slope described the viscosity. The shear rate independent viscosity was evaluated, and the middle value was used.
  • composition A (API-HPC-PVPK12-SDS) had a lower viscosity than composition B (API-HPC-SDS).
  • composition B was so high, that it was not possible to separate the milling beads from the high viscous composition B during wet milling. Hence it was not practical to process composition B into nanosuspension via wet milling.
  • the processing of composition A via wet milling on the other hand was unproblematic and resulted in a stable high active ingredient nanosuspension. Separation of grinding beads from the nanosuspension was possible.
  • a high active ingredient nano-suspension could also be generated using only a anionic surfactant here SDS and a low molecular weight non-ionic surfactant PVP K12 composition C comprising 10.1 wt% API (here Rivaroxaban), 10wt% PVPK12 and 0.2 wt% SDS and 79.7 wt% water. was produced and processed into an aqueous nanosuspension. The resulting aqueous nano-suspension was instable after dilution and therefore unsuitable for further applications (Data not shown).
  • Fig. 6 shows the resulting particle size distribution after milling of composition A (10.5 wt% active ingredient). Milling conditions were used as described in example 8.
  • composition A was repeated with two other active ingredients (data not shown)
  • Viscosity was measured as described in example 1. Used were two compositions in aqueous suspension one composition comprising 3 wt% HPC and 0.2 wt% SDS and 96.8 wt% water whereas the lower graph (circles) represents a composition comprising 2 wt% HPC and 0.2 wt% SDS and 97.8 wt% water.
  • Table 2 demonstrates that with increasing PVP K12 content the viscosity was reduced until a plateau was reached. With further addition of PVP K12 the viscosity increased again.
  • HPC-SDS solutions (2wt% and 0.2 wt%) in water with varied amount of PVPK12 or PVPK25 were produced for a viscosity study.
  • SDS and HPC content were kept constant (2 wt% HPC and 0.2 wt% SDS) and the PVPK12/PVPK25 content was varied.
  • Fig 3 shows that low molecular weight PVP - here PVP K12 - was suitable for viscosity reduction of a HPC-SDS solution at least up to a value of 8 wt%.
  • addition of the high molecular weight non-ionic surfactant PVPK25 resulted in a reduction of viscosity if added up to 5wt%. Viscosity was measured as described in example 1.
  • HPC was replaced by HPMC to produce Cellulose-SDS solutions in water with different amount of PVPK12 for a viscosity study.
  • SDS (0,2wt%) and HPMC (2wt%) content were kept constant and the PVPK12 content was varied in the range of 0-15 wt%.
  • Fig 4 shows that addition of 1wt% to 4 wt% of PVPK12 still cause reduction of viscosity of the HPMC-SDS solution. Viscosity was measured as described in example 1.
  • HPC-PVP solutions in water with different anionic surfactants Na-Docusate (DOSS), Na-Deoxycholate and SDS were produced.
  • HPC concentration was constant at 2wt%
  • anionic surfactant concentration was constant at 0.2wt%.
  • PVPK12 concentration was varied from 0 to 16 wt%. Viscosity was measured as described in example 1. For better comparability of samples, the relative viscosity change was calculated and plotted against PVPK12 concentration.
  • ⁇ ⁇ rel ⁇ n ⁇ ⁇ 0 ⁇ 0 was used for calculation of relative viscosity change.
  • Fig 5 shows the impact of anionic surfactant on the viscosity reduction induced by PVPK12 addition. SDS (circles, lowest curve) has the strongest impact followed by DOSS (middle curve, triangles). Na-Deoxycholate (top curve, squares) containing solutions do not show a reduction of viscosity when PVPK12 is added.
  • API-microparticles were dispersed inside the prepared stabilizer solution.
  • the result were three microsuspensions:
  • microsuspensions were the starting material for the preparation of nanosuspensions via stirred media milling.
  • nano-suspensions were prepared from each of the three microsuspensions via stirred media milling in picoliq by hosokawa alpine. All suspensions were processed at 35°C with 2500-3000 rpm in 90 ml milling chamber until a constant particle size was reached. 80% of milling chamber volume was filled with 0.4-0.6 mm ZrOz grinding beads by silibeads.
  • the dilution of the nano-suspensions was carried out inside the storage tank of Mastersizer 3000.
  • the systems 1.1, 2 and 3 were diluted in 100 ml distilled water at room temperature and constant stirrer speed of 1750 rpm.
  • System 1.2 was diluted with PVPK12 and 0.2 wt% SDS instead of distilled water inside the storage tank of mastersizer 3000. At time point 0, all systems were diluted.
  • Fig. 7 The results are depicted in Fig. 7 .
  • the figure shows the x 90,3 over time i.e. the 90 % of all particles had the depicted size or were smaller as measured by laser diffraction.
  • the top graph (squares) ("system 1.1) represents an active ingredient (Rivaroxaban) 10 wt% nanosuspension which was stabilized with 10 wt% PVPK12 and 0.2 wt% SDS and measured at room temperature in 100 ml distilled water in mastersizer 3000 laser diffractometer by malvern.
  • the top middle graph (circles) (“system 1.2") represents the same suspension but measured in stabilizer solution containing 10wt% PVPK12 and 0.2 wt% SDS instead of distilled water inside the storage tank of Mastersizer 3000.
  • the top bottom graph (triangles) (“system 2”) represents an active ingredient nanosuspension (Rivaroxaban) (10 wt%) which was stabilized with 8 wt% PVPK12, 2 wt% HPC and 0.2 wt% SDS.
  • the bottom graph (no marking) (“system 3") represents an active ingredient (Rivaroxaban) 2 wt% nanosuspension which was stabilized with 2 wt% HPC and 0.2 wt% SDS and measured in 100ml distilled water at room temperature in mastersizer 3000 laser diffractometer by malvern. Hence in all cases the SDS concentration (0.2 wt%) was the same.
  • system 2 did not show any agglomeration, even though instead of 2 wt% (system 3), 10wt% API were used.
  • the triple stabilizer system ensured stability during and after dilution.
  • a triple stabilizer system will also stabilize the active ingredient nano-particles under physiological conditions i.e. during dilution in the gastro-intestinal tract.
  • Viscosity was measured with rotational viscometry with a modular compact rheometer (MCR) 302e (Anton Paar). A concentric cylinder geometry was used. Shear rate was varied logarithmic from 0.1 1/s to 1000 1/s. 6 measurement points per decade were used. The measurement time was varied form 10s for a shear rate of 0.1 1/s and 1s for 1000 1/s.
  • MCR modular compact rheometer
  • compositions were spray dried using the Labspraydryer by ProCept with the settings 110°C drying temperature, 0,3 m 3 /min volume flow rate of the drying gas, 0,4 bar spray nozzle pressure, 5,5 g/min volume flow rate of the composition to be dried at a spray nozzle diameter of 0,8 mm. Afterwards the spray dried material was redispersed in distilled water.
  • the tenary stabilizer system of Li et al. showed a higher viscosity compared to a stabilizer system with only two stabilizers. Therefore the ternary stabilizers system of Li et al. composed of a primary stabilizer (water soluble cellulose derivative, e.g. HPC), a nonionic surfactant (Pluronic ® F68), and an anionic surfactant (SDS) was effective in reduction of particle size, improving dissolution rate and physical stability but not in decreasing viscosity of a composition before and after wet comminution.
  • a primary stabilizer water soluble cellulose derivative, e.g. HPC
  • Pluronic ® F68 nonionic surfactant
  • SDS anionic surfactant
  • compositions were calculated from the compositions of Li et al. assuming 15 wt % API instead of 19.38 wt% API as given in Li et al. in Table 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

What is described herein relates to a compositions comprising
• a substance of a particle size between 1 µm and 100 µm and a solubility in water between 0.0001 g/l and 10 g/l
• at least 2 wt% of at least one cellulose based polymer
• at least one anionic surfactant,
• at least one non-ionic surfactant,
• wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10:1 and 1:10
• wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2,
• and wherein the concentration of the substance of a particle size between 1 µm and 100µm and a solubility in water between 0.0001 g/l and 10 g/l is in the range of 10.1 wt% to 15 wt%.

Description

  • Stabilizer systems are commonly used in the wet comminution of a poorly soluble active ingredients for the production of nanosuspensions, i.e. suspensions in which the active ingredient is present as particles in the submicron range (d90 <1 µm). Apart from stabilizing the poorly soluble active ingredients during production of nanosuspensions, the stabilizer systems are also often required to stabilize these active ingredient nanoparticles in the nanosuspensions themselves. Generally, employed are water-soluble polymers for steric stabilization and charged (ionic) surfactants for electrostatic stabilization of the active ingredient nanoparticles. For example Li et al. in 2019 (Improved dissolution and oral absorption by co-grinding active drug probucol and ternary stabilizers mixtures with planetary beads-milling method) described a probucol suspensions stabilized with HPC, F68 and SDS and found that within certain concentrations of the nonionic surfactant F68 (0%, 0.5%, and 1.0%), the active ingredient crystals decreased with the increase of the content of F68, while extra amount of F68 (2.0%) did not further facilitate the size reduction, For economic reasons, a high concentration of active ingredients in nanosuspensions is preferred. In order to generate nanosuspensions with a high concentration of active ingredient a higher concentration of the stabilizing polymer has to be used as well. However, there is a concentration limitation for certain stabilizing polymers, either because their solubility in water is too low or because the viscosity becomes too high for comminution at higher polymer concentrations. For example, cellulose derivatives such as hydroxypropyl cellulose (HPC), which can be used as stabilizing polymer, lead to relatively high viscosities even at low concentrations, making processing of active ingredients with HPC as stabilizing polymer via comminution challenging or even impossible. Thus, generally the concentration of the active ingredient had to be reduced if HPC was used as stabilizing polymer, thereby also reducing the concentration of the stabilizing polymer until a viscosity was reached that allowed processing and/or that allowed stabilization of the active ingredient nanoparticles in the nanosuspensions. Accordingly, active ingredients that are preferably stabilized with HPC could only be produced as a lower concentrated nanosuspension. Consequently, compared to higher concentrated suspensions, several batches had to be milled to produce a required amount of active ingredient nanoparticles. Therefore, there was a need to provide higher concentration suspensions of substances stabilized with HPC.
  • This need is met by providing a composition comprising
    • a substance of a particle size between 1 µm and 100 µm and a solubility in water between 0.0001 g/l and 10 g/l
    • at least 2 wt % of at least one cellulose based polymer
    • at least one anionic surfactant,
    • at least one non-ionic surfactant
    • wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10: 1 and 1:10
    • wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2,
    • and wherein the concentration of the substance of a particle size between 1 µm and 100 µm and a solubility in water between 0.0001 g/l and 10 g/l is in the range of 10,1 wt% to 15 wt%.
    BRIEF DESCRIPTION OF THE DRAWINGS
    • FIG 1 shows that a composition comprising a triple stabilizer system has a lower viscosity than a composition comprising two stabilizers.
    • FIG 2 shows that via adding PVP K12 to a composition as described herein the viscosity was reduced until a plateau was reached. With further addition of PVP K12 the viscosity was increased again. The upper graph (triangles) represents a composition comprising 3 wt% HPC and 0.2 wt% SDS whereas the lower graph (circles) represents a composition comprising 2 wt% HPC and 0.2 wt% SDS.
    • FIG. 3 shows that low molecular weight non-ionic surfactant PVPK12 or high molecular weight non-ionic surfactant PVPK25 resulted in a reduction of viscosity. The upper graph (triangles) represents a composition comprising 2 wt% HPC, 0.2 wt% SDS and PVP K25 whereas the lower graph (circles) represents a composition comprising 2 wt% HPC, 0.2 wt% SDS and PVP K12.
    • FIG. 4 shows that addition of 1wt% to 4 wt% of PVPK12 causes reduction of viscosity of the HPMC-SDS solution.
    • FIG. 5 shows that the polymer influences the critical micelle concentration of a surfactant i.e. that the viscosity is influenced when a surfactant is employed that, from literature, is known to interact favorably with the used polymer.
    • FIG 6 shows the resulting particle size distribution after milling of composition A (10.5 wt% active ingredient)
    • FIG. 7 shows that high active ingredient compositions comprising nano-particles i.e. nanosuspensions are stable even when diluted.
    • FIG. 8 shows that with increasing HPC content in a system with only two stabilizers (SDS and HPC) the viscosity increases linearly.
    DEFINITIONS
  • As used herein, the term "particle" refers to a solid, gel, or semisolid material having a relatively small size and characterized in that as said particles have a solubility of less than 10g/l in a suspension comprising water, matrix forming polymer(s) and optionally surfactants as determined e.g. by HPLC.
  • As used herein the term "micro-particle" which is used synonymously with microparticle refers to particles having an average particle size of between > 999 nm to 100µm.
  • Preferably the employed micro-particles have an average d90 of between 2µm and 50µm, more preferably between 2µm and 30µm, most preferably between 2µm and 20µm.
  • As used herein the term "nano" refers to particles having an average particle size - i.e. d50 of the distribution - of ≥ 10 nm to ≤ 999 nm.
  • Herein the nanoparticles have a particle size distribution of d90 < 2µm, preferably < 1µm, especially preferred < 500 nm and d50 < 1 µm, preferably < 500 nm, especially preferred < 200 nm. The particle size distribution can be determined by methods known in the art such as laser diffraction or Dynamic Light Scattering (DLS). The term d50 or d90 means that 50% or 90% of the total product volume consists of particles smaller than the given value for d50 or d90. The given particle size corresponds to the hydrodynamic particle size when determined by DLS (dynamic light scattering), laser diffraction or electron microscopy and for all methods an equivalent size for spheres is given and meant here. A person skilled in the art is capable of choosing technical equipment suitable for achieving a respective d50 or d90 value. For example it is clear to a skilled person that using an agitated ball mill will result in a smaller d50 and d90 values than using a planetary ball mill, especially if the agitated ball mill is cooled.
  • If Laser diffraction was used to determine the particle size said laser diffraction was performed in a Malvern Mastersizer 3000. Suspensions (nano- and micro-) were directly injected into the storage tank of Master sizer 3000 without addition of further excipients. The Mastersizer 3000 was equipped with a Hydro MV unit, where deionized water was provided to disperse and dilute the sample further. The dispersed sample was added to the Hydro MV unit until the obscuration reached 5%. The mixer of the Hydro MV unit was set to 2500 rpm. The first three measurements were performed with red and blue laser lights using the Mie light scattering model. Three measurements were performed without ultrasonic.
  • As used herein the term "active ingredient" refers to an agent, active ingredient, compound, substance, compositions, or mixtures thereof, that provides a pharmacological and/or agrochemical effect.
  • As used herein the term "critical micelle concentration" (CMC) refers to the minimum concentration of surfactants which is necessary to form a colloidal system, in particular micelles, in a self-assembly process. The critical micelle concentration can be determined as described in A. Fernández, N. González, W. Iglesias, and L. Montenegro (1997) Determination of Critical Micelle Concentration of Some Surfactants by Three Techniques, J. Chemical Education, 74:1227-1231.) Preferably the CMC is measured via surface tension measurements with a tensiometer. Surfactant solutions with different concentrations are prepared and characterized with tensiometer as described in Masouk et al. 2022. Before CMC the surface tension is decreasing with increasing surfactant concentration. At CMC the surface tension is no longer reduced with increasing surfactant concentration.
  • Fig. 5 shows that surfactants which show no reduction of CMC (indicator for poor interaction with polymer) with PVP in the system (Na-Deoxycholate) do not influence the viscosity reduction of the triple-stabilizer-system. Hence a skilled person can determine whether a given surfactant is suitable for the composition described herein.
  • Hence what is described herein relates also to a composition comprising
    • a substance of a particle size between 1 µm and 100 µm and a solubility in water between 0.0001 g/l and 10 g/l
    • at least 2 wt % of at least one cellulose based polymer
    • at least one anionic surfactant, wherein the critical micelle concentration of the at least one anionic surfactant is influenced by the at least one cellulose based polymer or non-ionic surfactant(Indicator for good interaction between polymer/non-ionic surfactant and anionic surfactant
    • at least one non-ionic surfactant
    • wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10:1 and 1:10
    • wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2,
    • and wherein the concentration of the substance of a particle size between 1 µm and 100 µm and a solubility in water between 0.0001 g/l and 10 g/l is in the range of 10.1 wt% to 15 wt%.
  • As used herein the term "non-ionic surfactant " refers to surfactants that do not have any ions. The non-ionic surfactant sterically stabilizes the nano-particles and is hence also referred to as steric stabilizer.
  • DETAILED DESCRIPTION
  • As specified above according to a first aspect what is described herein relates to a composition comprising
    • a substance of a particle size between 1 µm and 100 µm and a solubility in water between 0.0001 g/l and 10 g/l
    • at least 2 wt% of at least one cellulose-based polymer
    • at least one anionic surfactant,
    • at least one non-ionic surfactant
    • wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10: 1 and 1:10
    • wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2,
    • and wherein the concentration of the substance of a particle size between 1 µm and 100 µm and a solubility in water between 0.0001 g/l and 10 g/l is in the range of 10.1 wt% to 15 wt%.
  • It is clear to a skilled person, that the remaining weight percentage proportion of the composition described herein is water. Preferably the water is distilled water and/or sterile water.
  • It was found that via adding the non-ionic surfactant to generate a triple stabilizer system, the viscosity of an aqueous composition comprising at least 2 wt% of a cellulose based polymer and a non-ionic surfactant in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10: 1 and 1: 10 before and after wet comminution was reduced. This was surprising as it had been expected that adding a further non-ionic surfactant would further increase the viscosity. Therefore, via adding the non-ionic surfactant to generate a triple stabilizer system, it became possible to increase concentration of the at least one cellulose-based polymer while still maintaining the viscosity in a range suitable for comminution/milling. Due to the higher cellulose based polymer concentration also concentration of the substance with a solubility in water between 0.0001 g/l and 10 g/l could be increased. Thus, employing the non-ionic surfactant resulted in a more economic process since the comminution has to be repeated less times. In addition, it was found that via adding the non-ionic surfactant to generate a triple stabilizer system supporting a higher concentration of the substance ensuring a ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance between 2:1 to 1:2 the particles size distribution (PSD) of the nanoparticles derived from the composition described herein remained almost exactly constant after drying and redispersing compared to the PSD of the nanoparticles derived from the composition described herein prior to drying.
  • Viscosity can be measured for example via rotational viscosimeter, capillary viscosimeter, falling sphere viscosimeter or dip cup viscosimeter which all are established methods and well known to a person skilled in the art. An example for a rotational viscosimeter is the modular compact rheometer MCR102e by Anton Paar. For flow and viscosity curves measured via rotational viscometry, a shear rate range is specified, and the viscosity is measured as a function of the shear rate. In the case of the flow curve, the shear stress is usually shown on the y-axis and the shear rate on the x-axis; in the case of the viscosity curve, the viscosity is shown on the y-axis and the shear rate on the x-axis. (Rotational viscometry :: Anton Paar Wiki (anton-paar.com).
  • In a preferred embodiment of the composition the substance of a particle size between 1 µm and 100 µm and a solubility in water between 0.0001 g/l and 10 g/l is an active ingredient hence the composition described herein comprises in an aqueous suspension
    • an active ingredient of a particle size between 1 µm and 100 µm and a solubility in water between 0.0001 g/l and 10 g/l
    • at least 2 wt% of at least one cellulose-based polymer
    • at least one anionic surfactant,
    • at least one non-ionic surfactant
    • wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10: 1 and 1: 10
    • wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the active ingredient is between 2:1 to 1:2,
    • and wherein the concentration of the active ingredient of a particle size between 1 µm and 100 µm and a solubility in water between 0.0001 g/l and 10 g/l is in the range of 10.1 wt% to 15 wt%.
  • A skilled person is aware of the fact that the composition described herein could also comprise more than one substance e.g. a mixture of two active ingredients. However, in practice this embodiment seems unlikely due to regulatory requirements regarding active ingredients.
  • Preferably, the cellulose-based polymer is selected from methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxybutylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, sodiumcarboxymethylcellulose, carboxymethylethylcellulose and carboxyalkylcellulose More preferably the cellulose based polymer is selected from hydroxymethylcellulose (HPMC) and hydroxypropylcellulose (HPC).
  • In an especially preferred embodiment HPC is used as cellulose based polymer. In a further preferred embodiment the composition comprises HPC in a range of between 2 wt% and 3 wt%.
  • In a preferred embodiment the anionic surfactant is chosen from the group consisting of sodium dodecyl sulfate (SDS), sodium docusate (dioctyl sodium sulfosuccinate) and/or sodium oleate.
  • In an especially preferred embodiment the anionic surfactant is sodium dodecyl sulfate (SDS).
  • When employing an anionic surfactant the composition described herein also has beneficial effects for the production of redispersible powders as described in WO2021069350A1 . To produce re-dispersible powders after drying of these nanosuspensions, it was shown in WO2021069350A1 that a drug to polymer ratio of ~1:1 is advantageous. By redispersible powders it is meant that these powders, with the addition of the at least equal amount of water removed during drying, form a suspension with a size distribution where again the d90 is < 1µm. If the suspension has a higher concentration less water has to be evaporated during drying to obtain the desired amount of redispersible powder ( WO2021069350A1 ).
  • To a person skilled in the art it is clear that also a surfactant other than an anionic surfactant can be used. The surfactant can be selected from any surfactant (i.e. charged or non-charged) as long as the critical micelle concentration of the surfactant is influenced by the cellulose based polymer (indicator for good interaction between anionic surfactant and used polymers / nonionic surfactants). If this is the case than the surfactant is suitable.
  • Surfactants known to a skilled person include charged surfactant selected from acylamino acids (and salts thereof), such as: acylglutamates, for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium acaprylglutamate; acylpeptides, for example palmitoyl hydrolyzed milk protein, sodium cocoyl hydrolyzed soy protein and sodium/potassium cocoyl hydrolyzed collagen; Sarcosinates, for example, myristoyl sarcosine, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate; Taurates, for example, sodium lauroyl taurate and sodium methyl cocoyl taurate; acyl lactylates, luroyl lactylate, caproyl lactylate, alaninates; carboxylic acids and derivatives, such as: carboxylic acids, for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate; ester carboxylic acids, for example calcium stearoyl lactylate and sodium PEG lauramide carboxylate; Ether carboxylic acids, for example sodium laureth carboxylate and sodium PEG cocamide carboxylate; phosphoric acid esters and salts, such as DEA-oleth-phosphate and dilaureth-phosphate; sulfonic acids and salts, such as acyl-isethionates, e.g. sodium/ammonium cocoyl isethionate, alkyl aryl sulfonates, alkyl sulfonates, for example sodium coco monoglyceride sulfate, sodium C-olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG cocamide sulfate, sulfosuccinates, for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate; as well as sulfuric acid esters, such as alkyl ether sulfate, for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C-pareth sulfate, alkyl sulfates, for example sodium, ammonium and TEA lauryl sulfate,, alkylamines, alkylimidazoles, ethoxylated amines, quaternary surfactants, esterquats and amphoteric surfactants such as Acyl/dialkyl ethylenediamines, for example sodium acylamphoacetate, disodium acylamphodipropionate, disodium alkylamphodiacetate, sodium acylamphohydroxypropyl sultonate, disodium acylamphodiacetate and sodium acylamphopropionate, and N-alkylamino acids, for example, aminopropylalkylglutamide, alkylaminopropionic acid, natuium alkylimidodipropionate and lauroamphocarboxyglycinate.
  • Examples of non-ionic surfactants are polyvinylpyrrolidone-vinylacetate-copolymer, polymethracrylate-derivates, and polyvinylpyrrolidone (PVP). methylcellulose, hydroxymethylcellulose, hydroxyethylellulose, hydroxypropylcellulose, hydroxybutylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, sodiumcarboxymethylcellulose, carboxymethylethylcellulose, carboxyalkylcellulose ester, starches, sodium carboxymethylamylopectin, chitosan, dextran sulfate sodium salt, alginic acid, alkali metal and ammonium salts of alginic acid, carrageenans, galactomannans, tragacanth, agar-agar, gum arabic, guar gum, xanthan gum, polyacrylic acid and its salts, polymethacrylic acid and its salts, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene oxide, polypropylene oxide, copolymers of ethylene oxide and propylene oxide, N-vinylpyrrolidone-vinyl acetate copolymers or a mixture of at least two of the aforementioned polymers. Polyvinylpyrrolidones (especially K12 and K30 types) and N-vinylpyrrolidone-vinyl acetate copolymers are particularly preferred. Preferably, the polymer can be a copolymer of ethylene oxide and propylene oxide, in particular a poloxamer, or a polyvinylpyrrolidone, in particular PVPK30.
  • In a further preferred embodiment the non-ionic surfactant is characterized by a molecular weight between 2,000 g/mol and 16,000g/mol preferably between 3,000 g/mol and 8,000 g/mol and is termed a "low molecular weight non-ionic surfactant ".
  • In a further preferred embodiment the non-ionic surfactant is characterized by a molecular weight between 18.000 g/mol and 50.000g/mol preferably between 22.000 g/mol and 44.000 g/mol and termed a "high molecular weight non-ionic surfactant ".
  • In another preferred embodiment the composition comprises 0.01 wt% to 10 wt% low molecular weight non-ionic surfactant or 0.01 wt% to 5wt% high molecular weight non-ionic surfactant.
  • In a preferred embodiment polyvinylpyrrolidone is used as non-ionic surfactant.
  • In an especially preferred embodiment the low molecular weight non-ionic surfactant is PVP K12.
  • In a preferred embodiment of the composition the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 4:1 and 1:4.
  • In a further preferred embodiment of the composition the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2. In an especially preferred embodiment of the of the composition the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1:1, as this ratio is optimal for the generation of re-dispersible powders.
  • In another preferred embodiment of the composition the concentration of the substance of a particle size between 1 µm and 100 µm in the range of 10.1 wt% to 12 wt%.
  • In another preferred embodiment of the composition the solubility of the substance of a particle size between 1 µm and 100 µm in water is in the range of between 0.001g/l and 1 g/l.
  • In another preferred embodiment the composition consist of at least one active ingredient of a particle size between 1µm and 100µm and a solubility in water between 0.001 g/l and 1 g/l, HPMC as cellulose based polymer, SDS as anionic surfactant, PVP12 as low molecular weight non-ionic surfactant , wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 4:1 and 1:4, wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1:1 and wherein the concentration of the active ingredient of a particle size between 1 µm and 100µm and a solubility in water between 0.001 g/l and 10 g/l is in the range of 10.1 wt% to 12 wt%.
  • In an especially preferred embodiment the composition consist of at least one active ingredient of a particle size between 1µm and 100µm and a solubility in water between 0.001 g/l and 1 g/l, 2 wt% HPC as cellulose based polymer, SDS as anionic surfactant, PVP12 as low molecular weight non-ionic surfactant, wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 4:1 and 1:4, wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1:1 and wherein the concentration of the active ingredient of a particle size between 1µm and 100 µm and a solubility in water between 0.001 g/l and 10 g/l is in the range of 10.1 wt% to 12 wt%.
  • In another especially preferred embodiment the composition consist of at least one active ingredient of a particle size between 1µm and 100µm and a solubility in water between 0.001 g/l and 1 g/l, 3 wt% of HPC as cellulose based polymer, SDS as anionic surfactant, PVP12 as low molecular weight non-ionic surfactant, wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 4:1 and 1:4, wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1:1 and wherein the concentration of the active ingredient of a particle size between 1µm and 100 µm and a solubility in water between 0.001 g/l and 10 g/l is in the range of 10.1 wt% to 12 wt%.
  • In a preferred embodiment the composition is further processed to form a re-dispersible powder as described in WO2021069350A1 . In detail the composition in this case is further process via nano-grinding thereby providing a composition comprising nano-particles of the substance characterized by a nano-particle size of a d90 between 10 nm and 999 nm as measured by Dynamic Light Scattering (DLS), laser diffraction or electron microscopy.
  • Suitable methods of nano-grinding (also termed nano grinding, nanogrinding or nanomilling) can be selected from the group consisting of wet bead milling in stirred media mills, wet bead milling in planetary mills - especially suitable for small amounts - and high pressure homogenization. Alternatively, the application of high shear forces in aqueous suspensions like in a high pressure homogenization process or the application of high impact forces between the particles like in a microfluidizer can be used to produce nano-particles.
  • To a skilled person it is clear that if nano grinding is used for providing the seeding material (i.e. production of nanoscale crystals) said nano grinding can only be performed if the nano-particles are not completely dissolved. Hence the skilled person would choose a suitable temperature within the temperature range of between 253 K and 323 K, preferably between 273 K and 303 K for nano-grinding the nano-particles in the aqueous suspension.
  • Preferably, if nano-grinding is used, a preferred nano-grinding time is observed during grinding in order to achieve better redispersion of the dried powder containing nanoparticles. This preferred grinding time (t-preferred) is significantly longer than the grinding time that would typically be required to achieve the necessary particle size. Preferably said preferred grinding time (t-preferred) is at least 1.5 times t0, preferably it is at least 2 times t0 and particularly preferably at least 4 times t0. Here, t0 is considered to be the usual grinding time at which the d90 value of the particle size distribution is 1.5 times the d90 value reached after 12 hours and is referred to as d90(12h). In other words, this means that d90 (12h) is 2/3 of the d90 value at the usual grinding time t0. Grinding time is understood to mean the residence time of the suspension in the mill, which explicitly means that the possible residence time of the suspension in an optionally present holding tank is not counted towards the grinding time, i.e. towards the comminution time (tz).
  • Following nano-grinding the composition is spray dried according to step B) of the method described in WO 2021/069350 and to form a powder and optionally further process to form a tablet. This has the advantage that it can be stored more conveniently.
  • In addition, as mentioned above it was found that via adding the non-ionic surfactant to generate a triple stabilizer system supporting a higher concentration of the substance and ensuring a ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance between 2:1 to 1:2, the particles size distribution (PSD) of the nanoparticles derived from the composition described herein remained almost exactly constant after drying and redispersing compared to the PSD of the nanoparticles derived from the composition described herein prior to drying. In contrast for example the nanosuspension described by Li et al. 2019 does not show an almost exactly constant PSD after redispersing (cf. Example 9).
  • In other words, drying and redispersion of a composition comprising nanoparticles obtained from the composition described herein in aqueous media that do not bring about complete molecular dissolution of the substance, lead to the particle size distribution (PSD) of the original composition comprising nanoparticles obtained from the composition described herein remaining almost exactly constant hence differs by comparison with the PSD of the redispersed powder only by a factor X within a range from ≥ 1 to ≤ 3, based on the d90 value of the respective suspensions. X here corresponds to the ratio n/v, where n represents the d90 value of the PSD after drying and redispersion and v the d90 value before drying. X is particularly preferably ≥ 1 to ≤ 1.2.
  • It is especially preferred that if the composition is processed via nano-grinding and spray drying the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1: 1.Alternatively to nano-grinding the seeding material (i.e. the nano crystals) can be provided via high pressure homogenization, or antisolvent precipitation.
  • In another aspect what is described herein relates to a method for producing a composition comprising nano-particles starting from the composition described herein, wherein the method comprises the following steps:
    • providing composition as described above comprising in an aqueous suspension a substance of a particle size between 1 µm and 100µm and a solubility in water between 0.0001 g/l and 10 g/l, at least 2 wt % of at least one cellulose based polymer, at least one anionic surfactant and at least one non-ionic surfactant, wherein the at least one non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10:1 and 1:10 wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance a particle size between 1µm and 1 nm is between 2:1 to 1:2, and wherein the concentration of the substance in the range of 10.1 wt% to 15 wt%.
    • comminution of the composition for a time span until the particle size stays constant in a temperature range between 253K and 323 K thereby generating the composition comprising nano-particles.
  • Preferably this aspect relates to a method for producing a composition comprising nano-particles starting from the composition described herein, wherein the method comprises the following steps:
    1. a) providing composition as described above comprising an active ingredient of a particle size between 1 µm and 100µm and a solubility in water between 0.0001 g/l and 10 g/l, at least 2wt% of at least one cellulose based polymer, at least one anionic surfactant and at least one non-ionic surfactant, wherein the at least one non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10:1 and 1:10 wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance a particle size between 1µm and 1 nm is between 2:1 to 1:2, and wherein the concentration of the substance in the range of 10.1 wt% to 15 wt%.
    2. b) comminution of the composition for a time span until the particle size stays constant in a temperature range between 253K and 323 K thereby generating the composition comprising nano-particles
    3. c) drying the mixture comprising nanoparticles obtained in step B)
    4. d) re-dispersing the powder obtained in step D)
  • As mentioned above this method and the resulting re-dispersible powder have the advantage that a high concentration of active ingredient can be processes and the particles size distribution (PSD) of the nanoparticles remains almost exactly constant after drying and redispersing compared to the PSD of the nanoparticles derived from the composition described herein prior to drying.
  • In yet another aspect what is described herein relates to a composition comprising
    • a substance of a particle size between 1 nm and 999 nm and a solubility in water between 0.0001 g/l and 10 g/l
    • at least 2wt % of at least one cellulose based polymer
    • at least one anionic surfactant,
    • at least one non-ionic surfactant,
    • wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10: 1 and 1: 10
    • wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2,
    • and wherein the concentration of the substance of a particle size between 1µm and 100µm and a solubility in water between 0.0001 g/l and 10 g/l is in the range of 10.1 wt% to 15 wt% for use as a medicament.
  • Said composition for use as a medicament is preferably a nano-suspension. Said composition is preferably manufactured via the method for producing a composition comprising nano-particles described above.
  • EXAMPLES 1. Viscosity of a triple stabilizer system compared to a composition comprising two stabilizers
  • In this example two compositions were compared. Composition A was an aqueous i.e. water-based suspension comprised as substance an active ingredient (10.5 wt%, here Rivaroxaban), as the at least one cellulose-based polymer hydroxypropylcellulose (HPC) 2 wt%, as the at least one anionic surfactant a charged surfactant here SDS (0.2% SDS) and as the at least one non-ionic surfactant a low molecular weight non-ionic surfactant PVP K12 (8 wt%) and 79.3 wt% water.
  • Composition B comprised 10.5 wt % active ingredient (here Rivaroxaban), 10 wt % HPC and 0.2 wt % SDS. The components of both compositions were stirred on a magnetic stirrer at room temperature.
  • Viscosity was measured with rotational viscometry with a modular compact rheometer (MCR) 302e (Anton Paar). A concentric cylinder geometry was used. Shear rate was varied logarithmic from 0.1 1/s to 1000 1/s. 6 measurement points per decade were used. The measurement time was varied form 10s for a shear rate of 0.1 1/s and 1s for 1000 1/s. Shear rate vs. Shear stress was plotted. The slope described the viscosity. The shear rate independent viscosity was evaluated, and the middle value was used.
  • As depicted in Fig. 1 it was found that composition A (API-HPC-PVPK12-SDS) had a lower viscosity than composition B (API-HPC-SDS).
  • 2. High active ingredient nanosuspension
  • Furthermore, the viscosity of composition B was so high, that it was not possible to separate the milling beads from the high viscous composition B during wet milling. Hence it was not practical to process composition B into nanosuspension via wet milling. The processing of composition A via wet milling on the other hand was unproblematic and resulted in a stable high active ingredient nanosuspension. Separation of grinding beads from the nanosuspension was possible.
  • To evaluate whether a high active ingredient nano-suspension could also be generated using only a anionic surfactant here SDS and a low molecular weight non-ionic surfactant PVP K12 composition C comprising 10.1 wt% API (here Rivaroxaban), 10wt% PVPK12 and 0.2 wt% SDS and 79.7 wt% water. was produced and processed into an aqueous nanosuspension. The resulting aqueous nano-suspension was instable after dilution and therefore unsuitable for further applications (Data not shown). Fig. 6 shows the resulting particle size distribution after milling of composition A (10.5 wt% active ingredient). Milling conditions were used as described in example 8.
  • The results of composition A were repeated with two other active ingredients (data not shown) 3. Influence of non-ionic surfactant (PVP) concentration
  • Moreover, it was found that with increasing PVP K12 content the viscosity was reduced until a plateau was reached. With further addition of PVP K12 the viscosity increased again (Fig. 2). Viscosity was measured as described in example 1. Used were two compositions in aqueous suspension one composition comprising 3 wt% HPC and 0.2 wt% SDS and 96.8 wt% water whereas the lower graph (circles) represents a composition comprising 2 wt% HPC and 0.2 wt% SDS and 97.8 wt% water. Table 2
    PVPK12 HPC 2 wt% HPC 3wt%
    0.0 14.29 30.23
    0.5 13.42 no data point
    1.0 12.36 25.94
    2.0 10.90 23.65
    4.0 9.78 21.94
    8.0 9.68 22.72
    16.0 14.68 32.87
  • Table 2 demonstrates that with increasing PVP K12 content the viscosity was reduced until a plateau was reached. With further addition of PVP K12 the viscosity increased again.
  • 4. Influence of non-ionic surfactant other than PVP 12
  • In this example HPC-SDS solutions (2wt% and 0.2 wt%) in water with varied amount of PVPK12 or PVPK25 were produced for a viscosity study. SDS and HPC content were kept constant (2 wt% HPC and 0.2 wt% SDS) and the PVPK12/PVPK25 content was varied. Fig 3 shows that low molecular weight PVP - here PVP K12 - was suitable for viscosity reduction of a HPC-SDS solution at least up to a value of 8 wt%. Also, addition of the high molecular weight non-ionic surfactant PVPK25 resulted in a reduction of viscosity if added up to 5wt%. Viscosity was measured as described in example 1.
  • 5. Influence of cellulose-based polymer other than HPC
  • In this example HPC was replaced by HPMC to produce Cellulose-SDS solutions in water with different amount of PVPK12 for a viscosity study. SDS (0,2wt%) and HPMC (2wt%) content were kept constant and the PVPK12 content was varied in the range of 0-15 wt%. Fig 4 shows that addition of 1wt% to 4 wt% of PVPK12 still cause reduction of viscosity of the HPMC-SDS solution. Viscosity was measured as described in example 1.
  • 6. Influence of anionic surfactants other than SDS
  • In this example HPC-PVP solutions in water with different anionic surfactants Na-Docusate (DOSS), Na-Deoxycholate and SDS were produced. HPC concentration was constant at 2wt%, anionic surfactant concentration was constant at 0.2wt%. PVPK12 concentration was varied from 0 to 16 wt%. Viscosity was measured as described in example 1. For better comparability of samples, the relative viscosity change was calculated and plotted against PVPK12 concentration. Δ η rel = η n η 0 η 0
    Figure imgb0001
    was used for calculation of relative viscosity change. η o represents the viscosity of the respective cellulose derivative anionic surfactant solution without PVP and ηn the respective viscosity of the cellulose derivative anionic surfactant solutions after PVP has been added. If ηn = η 0 the resulting relative viscosity change is zero. Fig 5 shows the impact of anionic surfactant on the viscosity reduction induced by PVPK12 addition. SDS (circles, lowest curve) has the strongest impact followed by DOSS (middle curve, triangles). Na-Deoxycholate (top curve, squares) containing solutions do not show a reduction of viscosity when PVPK12 is added. It is literature known that Na-Deoxycholate does not have a good interaction with PVP or cellulose derivates (Majhi, 2000, physicochemical investigations on the interaction of surfactants and salts with polyvinylpyrrolidone in aqueous medium). In other words the data shows that the viscosity was not influenced by nonionic surfactant PVP when an anionic surfactant with poor interaction with used non-ionic surfactant and the cellulose derivates (i.e. the polymer) was employed suggesting that nonionic surfactant PVP/ cellulose derivate HPC solution did not influence the CMC of the anionic surfactant Na-Deoxycholate. Indicator for poor interaction could be shown with surface tension measurements were the CMC of Na-Deoxycholate was not influenced by used polymers (Majhi, 2000). Hence in this example the viscosity of triple stabilizer system was influenced when the anionic surfactants Na-Docusate (DOSS) and SDS were used. CMC of those ionic surfactants are expected to be influenced by PVP and HPC. Therefore Na-Docusate (DOSS) and SDS were suitable (anionic) surfactants.
  • 7. Influence of increasing HPC in a system with two stabilizers
  • In this example water-based HPC-SDS solutions (i.e. solutions with only two stabilizers) were prepared with constant SDS-concentration (0.2wt%) and varied HPC-concentration. Fig. 8 shows that with increasing HPC content the viscosity increases linearly. Viscosity was measured as described in example 1.
  • 8. Dilution experiments
  • In order to show that the high active ingredient compositions are stable even when diluted as it would be the case if an active ingredient is applied to a subject, different settings were compared In first step aqueous stabilizer solutions were prepared
    1. (1) 10 wt% PVPK12, 0.2 wt% SDS,
    2. (2) 8 wt% PVPK12, 2 wt% HPC and 0.2 wt% SDS and
    3. (3) 2 wt% HPC and 0.2 wt% SDS.
  • After that API-microparticles were dispersed inside the prepared stabilizer solution. The result were three microsuspensions:
    1. (1) active ingredient (Rivaroxaban) 10 wt% ,10 wt% PVPK12, 0.2 wt% SDS
    2. (2) active ingredient (Rivaroxaban) 10 wt% 8 wt% PVPK12, 2 wt% HPC and 0.2 wt% SDS
    3. (3) active ingredient (Rivaroxaban) 2 wt% 2 wt% HPC and 0.2 wt% SDS
  • These microsuspensions were the starting material for the preparation of nanosuspensions via stirred media milling. In the next step nano-suspensions were prepared from each of the three microsuspensions via stirred media milling in picoliq by hosokawa alpine. All suspensions were processed at 35°C with 2500-3000 rpm in 90 ml milling chamber until a constant particle size was reached. 80% of milling chamber volume was filled with 0.4-0.6 mm ZrOz grinding beads by silibeads.
  • The dilution of the nano-suspensions was carried out inside the storage tank of Mastersizer 3000. The systems 1.1, 2 and 3 were diluted in 100 ml distilled water at room temperature and constant stirrer speed of 1750 rpm. System 1.2 was diluted with PVPK12 and 0.2 wt% SDS instead of distilled water inside the storage tank of mastersizer 3000. At time point 0, all systems were diluted.
  • The results are depicted in Fig. 7. The figure shows the x90,3 over time i.e. the 90 % of all particles had the depicted size or were smaller as measured by laser diffraction. The top graph (squares) ("system 1.1) represents an active ingredient (Rivaroxaban) 10 wt% nanosuspension which was stabilized with 10 wt% PVPK12 and 0.2 wt% SDS and measured at room temperature in 100 ml distilled water in mastersizer 3000 laser diffractometer by malvern. The top middle graph (circles) ("system 1.2") represents the same suspension but measured in stabilizer solution containing 10wt% PVPK12 and 0.2 wt% SDS instead of distilled water inside the storage tank of Mastersizer 3000. The top bottom graph (triangles) ("system 2") represents an active ingredient nanosuspension (Rivaroxaban) (10 wt%) which was stabilized with 8 wt% PVPK12, 2 wt% HPC and 0.2 wt% SDS. The bottom graph (no marking) ("system 3") represents an active ingredient (Rivaroxaban) 2 wt% nanosuspension which was stabilized with 2 wt% HPC and 0.2 wt% SDS and measured in 100ml distilled water at room temperature in mastersizer 3000 laser diffractometer by malvern. Hence in all cases the SDS concentration (0.2 wt%) was the same.
  • It was found that the dilution of system 1.1 inside water resulted in an instable composition since the nanoparticles agglomerated and formed larger particles in case of PVP stabilized nanosuspension.
  • Dilution with PVP in water (system 1.2) did not have this effect because the PVP in solution at the concentration used herein in the dilution medium ensured the stability of the diluted nanoparticles
  • System 3 did not show any agglomeration during the measurement time. However, it contained only 2wt% active ingredient.
  • Also, system 2 did not show any agglomeration, even though instead of 2 wt% (system 3), 10wt% API were used. Hence the triple stabilizer system ensured stability during and after dilution. Hence it can be concluded that a triple stabilizer system will also stabilize the active ingredient nano-particles under physiological conditions i.e. during dilution in the gastro-intestinal tract.
  • 9. Comparison to ternary stabilizer system
  • As described above the publication Li et al. 2019 is known that described the use of an aqueous ternary stabilizer system. However, the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance in Li et al is 6.5: 1 and not between 2: 1 to 1:2. To demonstrate that this ratio does not lead to a reduced viscosity and a redispersible powder the following experiment was conducted:
    Two composition as given below in Table 1 were generated and the components of both compositions were stirred on a magnetic stirrer at room temperature.
  • Viscosity was measured with rotational viscometry with a modular compact rheometer (MCR) 302e (Anton Paar). A concentric cylinder geometry was used. Shear rate was varied logarithmic from 0.1 1/s to 1000 1/s. 6 measurement points per decade were used. The measurement time was varied form 10s for a shear rate of 0.1 1/s and 1s for 1000 1/s.
  • The compositions were spray dried using the Labspraydryer by ProCept with the settings 110°C drying temperature, 0,3 m3/min volume flow rate of the drying gas, 0,4 bar spray nozzle pressure, 5,5 g/min volume flow rate of the composition to be dried at a spray nozzle diameter of 0,8 mm. Afterwards the spray dried material was redispersed in distilled water.
    Li et al (wt%) Composition I (wt%) Composition II (wt%) Composition of Example 1 (wt%)
    API 19.38 wt% 10.1 wt% (x 1.92 = 19.4) 10.1 wt% (x 1.92 = 19.4) 10.5
    SDS 0.78 wt% 0.2 wt% (x1.92 = 0.34 0.2 wt% 0.2
    PVP 0.78 wt% (F68 not PVP) 0.404 wt% (x 1.92 = 0.78) 0 wt% 8
    HPC 1.55 wt% 0.808 wt% (x 1.92 = 1.55) 0.808 wt% 2
    Ratio API: (HPC+PVP) 8.33 8.33 10.5:10 = 1.05
    Viscosity 2.579955 2.1306525
    Redispersible after drying No No (milled) Yes
    D90: 0,416 µm (milled) D90: 1,48 µm (milled) D90: 0,145 µm (milled)
    With constant D90: 16,3 µm (SD)
    Particle size D90: 14,4 µm (SD) D90: 0,146 µm (SD)
  • It can be seen from Table 1 that the tenary stabilizer system of Li et al. showed a higher viscosity compared to a stabilizer system with only two stabilizers. Therefore the ternary stabilizers system of Li et al. composed of a primary stabilizer (water soluble cellulose derivative, e.g. HPC), a nonionic surfactant (Pluronic ®F68), and an anionic surfactant (SDS) was effective in reduction of particle size, improving dissolution rate and physical stability but not in decreasing viscosity of a composition before and after wet comminution.
  • Furthermore the viscosity of the following to compositions was measured as described in example 1
    1. 1) 0.6 wt% PVP, 1.2 wt% HPC, 0.2 wt% SDS, 98 wt% water
    2. 2) 1.2 wt% HPC, 0.2 wt% SDS, 98.6 wt% water
  • These compositions were calculated from the compositions of Li et al. assuming 15 wt % API instead of 19.38 wt% API as given in Li et al. in Table 1.
  • The results are shown in Table 3 below: Table 3
    0.6 wt% PVP, 1.2 wt% HPC 0.2 wt% SDS 1.2 wt% HPC und 0.2 wt% SDS
    Viscosity In mPa*s 5.7 5.4
  • The results of Table 3 show that a least 2 wt% HPC need to be present for the viscosity reduction of a triple stabilizer system.

Claims (12)

  1. A compositions comprising
    • a substance of a particle size between 1 µm and 100 µm as measured by Laser diffraction and a solubility in water between 0.0001 g/l and 10 g/l
    • at least 2wt % of at least one cellulose based polymer
    • at least one anionic surfactant,
    • at least one non-ionic surfactant,
    • wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10: 1 and 1: 10
    • wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2,
    • and wherein the concentration of the substance of a particle size between 1µm and 100µm and a solubility in water between 0.0001 g/l and 10 g/l is in the range of 10.1 wt% to 15 wt%.
  2. Composition according to claim 1 wherein the composition the substance of a particle size between 1µm and 100µm and a solubility in water between 0.0001 g/l and 10 g/l is an active ingredient.
  3. Composition according to claim 1 wherein the cellulose based polymer is hydroxypropylcellulose HPC and is present in an amount in the range of between 2 wt% and 3 wt%.
  4. Composition according to claim 1 wherein the anionic surfactant is selected form the group consisting of sodium dodecyl sulfate (SDS), sodium docusate (dioctyl sodium sulfosuccinate) or sodium oleate.
  5. Composition according to claim 1, wherein the composition comprises 0.01 wt% to 10 wt% low molecular weight non-ionic surfactant or 0.01 wt% to 5wt% high molecular weight non-ionic surfactant.
  6. Composition according to claim wherein polyvinylpyrrolidone is used as non-ionic surfactant.
  7. Composition according to claim 6, wherein the low molecular weight non-ionic surfactant is PVP K12.
  8. Composition according to claim 1 wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 4:1 and 1:4 .
  9. Composition according to claim 1 wherein the composition consist of at least one active ingredient of a particle size between 1µm and 100µm as measured Laser diffraction and a solubility in water between 0.001 g/l and 1 g/l, at least 2 wt% HPC as cellulose based polymer, SDS as anionic surfactant, PVP12 as low molecular weight non-ionic surfactant, wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 4:1 and 1:4, wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is 1:1 and wherein the concentration of the active ingredient of a particle size between 1µm and 100 µm and a solubility in water between 0.001 g/l and 10 g/l is in the range of 10.1 wt% to 12 wt%.
  10. Method for producing a composition comprising nano-particles with the following steps:
    • providing a composition according to claim 1 comprising a substance of a particle size between 1µm and 100µm and a solubility in water between 0.0001 g/l and 10 g/l, at least 2 wt% of at least one cellulose based polymer, at least one anionic surfactant and at least one non-ionic surfactant, wherein the at least one non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10:1 and 1:10 wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance a particle size between 1µm and 1 nm is between 2:1 to 1:2, and wherein the concentration of the substance in the range of 10.1 wt% to 15 wt%.
    • comminution of the composition for a time span until the particle size stays constant in a temperature range between 253K and 323 K) thereby generating the composition comprising nano-particles.
  11. A composition manufactured by the method of claim 10 and therefore comprising
    • a substance of a particle size between 1 nm and 999 nm as measured by Dynamic Light Scattering (DLS) and a solubility in water between 0.0001 g/l and 10 g/l
    • at least 2 wt% of at least one cellulose based polymer
    • at least one anionic surfactant, at least one anionic surfactant
    • at least one non-ionic surfactant,
    • wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10:1 and 1:10
    • wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2,
    • and wherein the concentration of the substance of a particle size between 1 nm and 999 nm and a solubility in water between 0.0001 g/l and 10 g/l is in the range of 10.1 wt% to 15 wt%.
  12. A composition manufactured by the method of claim 10 comprising
    • a substance of a particle size between 1 nm and 999 nm as measured by Dynamic Light Scattering (DLS) and a solubility in water between 0.0001 g/l and 10 g/l
    • at least 2 wt% of at least one cellulose based polymer
    • at least one anionic surfactant, at least one anionic surfactant
    • at least one non-ionic surfactant,
    • wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10: 1 and 1: 10
    • wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2,
    • and wherein the concentration of the substance of a particle size between 1 nm and 999 nm and a solubility in water between 0.0001 g/l and 10 g/l is in the range of 10.1 wt% to 15 wt% for use as a medicament.
EP23190167.9A 2022-08-15 2023-08-08 Triple stabilizer system Pending EP4324458A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22190372.7A EP4324457A1 (en) 2022-08-15 2022-08-15 Triple stabilizer
EP23164885 2023-03-29

Publications (1)

Publication Number Publication Date
EP4324458A1 true EP4324458A1 (en) 2024-02-21

Family

ID=87519830

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23190167.9A Pending EP4324458A1 (en) 2022-08-15 2023-08-08 Triple stabilizer system

Country Status (2)

Country Link
US (1) US20240050370A1 (en)
EP (1) EP4324458A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2021069350A1 (en) 2019-10-10 2021-04-15 Bayer Aktiengesellschaft Process for producing a pharmaceutical formulation comprising active substance, polymer and surfactant
WO2021156223A1 (en) * 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2021069350A1 (en) 2019-10-10 2021-04-15 Bayer Aktiengesellschaft Process for producing a pharmaceutical formulation comprising active substance, polymer and surfactant
WO2021156223A1 (en) * 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. FERNANDEZN. GONZALEZW. IGLESIASL. MONTENEGRO: "Determination of Critical Micelle Concentration of Some Surfactants by Three Techniques", J. CHEMICAL EDUCATION, vol. 74, 1997, pages 1227 - 1231
BITTERLICH A ET AL: "Process parameter dependent growth phenomena of naproxen nanosuspension manufactured by wet media milling", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 92, 9 March 2015 (2015-03-09), pages 171 - 179, XP029226830, ISSN: 0939-6411, DOI: 10.1016/J.EJPB.2015.02.031 *
CERDEIRA ANA M ET AL: "Formulation and drying of miconazole and itraconazole nanosuspensions", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 443, no. 1, 4 January 2013 (2013-01-04), pages 209 - 220, XP028979329, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2012.11.044 *
LI ET AL., IMPROVED DISSOLUTION AND ORAL ABSORPTION BY CO-GRINDING ACTIVE DRUG PROBUCOL AND TERNARY STABILIZERS MIXTURES WITH PLANETARY BEADS-MILLING METHOD, 2019

Also Published As

Publication number Publication date
US20240050370A1 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
Wang et al. Stability of nanosuspensions in drug delivery
Lee et al. Characteristics of polymers enabling nano-comminution of water-insoluble drugs
Sun et al. Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption
Wu et al. Physical and chemical stability of drug nanoparticles
Lestari et al. Systematic screening of different surface modifiers for the production of physically stable nanosuspensions
Verma et al. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions
Cerdeira et al. Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability
Ali et al. Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling
Lasoń et al. Influence of process parameters on properties of Nanostructured Lipid Carriers (NLC) formulation
JP5317960B2 (en) Method for producing finely divided organic compound particles
Yu et al. Cellulose nanocrystals based clove oil Pickering emulsion for enhanced antibacterial activity
Kumar et al. Modification of the zeta potential of montmorillonite to achieve high active pharmaceutical ingredient nanoparticle loading and stabilization with optimum dissolution properties
Bitterlich et al. Challenges in nanogrinding of active pharmaceutical ingredients
Mathure et al. Formulation and evaluation of niosomal in situ nasal gel of a serotonin receptor agonist, buspirone hydrochloride for the brain delivery via intranasal route
Zhang et al. Nanosuspensions of poorly water soluble drugs prepared by top-down technologies
Paun et al. Nanosuspension: An emerging trend for bioavailability enhancement of poorly soluble drugs
Guan et al. The technology for improving stability of nanosuspensions in drug delivery
Nakach et al. Engineering of nano-crystalline drug suspensions: employing a physico-chemistry based stabilizer selection methodology or approach
CN112494492A (en) Aripiprazole prodrug compositions
Peltonen et al. Drug nanocrystals and nanosuspensions in medicine
EP4324458A1 (en) Triple stabilizer system
Slavkova et al. Formulation of Budesonide-Loaded Polymeric Nanoparticles into Hydrogels for Local Therapy of Atopic Dermatitis
EP3613415A1 (en) Method for preparing active material nanoparticles using lipid as lubricant for milling
EP4324457A1 (en) Triple stabilizer
Palani et al. Enhancement of rosuvastatin calcium bioavailability applying nanocrystal technology and in-vitro, in-vivo evaluations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240821

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR